Results of anti-VEGF treatment for neovascular AMD in eyes with different baseline visual acuity in Turkish population-based on real life data-Bosphorus retina study group.

Autor: Ozturk M; Ophthalmology Clinic, Haseki Training and Research Hospital, Istanbul 34096, Turkey. Electronic address: dr_mine@yahoo.com., Ozkaya A; Ophthalmology Clinic, Beyoglu Eye Training and Research Hospital, Istanbul 34421, Turkey., Karabas L; Department of Ophthalmology, Kocaeli University Faculty of Medicine, Kocaeli 41380, Turkey., Alagoz C; Ophthalmology Clinic, Beyoglu Eye Training and Research Hospital, Istanbul 34421, Turkey., Alkın Z; Ophthalmology Clinic, Beyoglu Eye Training and Research Hospital, Istanbul 34421, Turkey., Artunay O; Ophthalmology Clinic, Beyoglu Eye Training and Research Hospital, Istanbul 34421, Turkey., Bayramoglu SE; Ophthalmology Clinic, Kanuni Sultan Suleyman Training and Research Hospital, Istanbul 34303, Turkey., Bolukbasi S; Ophthalmology Clinic, Okmeydani Training and Research Hospital, Istanbul 34384, Turkey., Demir G; Ophthalmology Clinic, Beyoglu Eye Training and Research Hospital, Istanbul 34421, Turkey., Demir M; Ophthalmology Clinic, Sisli Etfal Training and Research Hospital, Istanbul 34360, Turkey., Demircan A; Ophthalmology Clinic, Beyoglu Eye Training and Research Hospital, Istanbul 34421, Turkey., Erden B; Ophthalmology Clinic, Okmeydani Training and Research Hospital, Istanbul 34384, Turkey., Erdogan G; Ophthalmology Clinic, Beyoglu Eye Training and Research Hospital, Istanbul 34421, Turkey., Erdogan M; Ophthalmology Clinic, Kanuni Sultan Suleyman Training and Research Hospital, Istanbul 34303, Turkey., Eris E; Ophthalmology Clinic, Beyoglu Eye Training and Research Hospital, Istanbul 34421, Turkey., Kaldirim H; Ophthalmology Clinic, Bagcilar Training and Research Hospital, Istanbul 34200, Turkey., Onur İU; Ophthalmology Clinic, Bakırkoy Dr. Sadi Konuk Training and Research Hospital, Istanbul 34147, Turkey., Osmanbasoğlu OA; Ophthalmology Clinic, Istanbul Training and Research Hospital, Istanbul 34098, Turkey., Erkul SO; Ophthalmology Clinic, Istanbul Training and Research Hospital, Istanbul 34098, Turkey., Perente İ; Ophthalmology Clinic, Beyoglu Eye Training and Research Hospital, Istanbul 34421, Turkey., Sarici K; Ophthalmology Clinic, Kanuni Sultan Suleyman Training and Research Hospital, Istanbul 34303, Turkey., Sayin N; Ophthalmology Clinic, Kanuni Sultan Suleyman Training and Research Hospital, Istanbul 34303, Turkey., Yasa D; Ophthalmology Clinic, Beyoglu Eye Training and Research Hospital, Istanbul 34421, Turkey., Yilmaz İ; Ophthalmology Clinic, Beyoglu Eye Training and Research Hospital, Istanbul 34421, Turkey., Yılmazabdurrahmanoglu Z; Ophthalmology Clinic, Bagcilar Training and Research Hospital, Istanbul 34200, Turkey.
Jazyk: angličtina
Zdroj: Photodiagnosis and photodynamic therapy [Photodiagnosis Photodyn Ther] 2023 Jun; Vol. 42, pp. 103640. Date of Electronic Publication: 2023 May 30.
DOI: 10.1016/j.pdpdt.2023.103640
Abstrakt: Background: To investigate the anatomical and visual outcomes of the patients with neovascular age-related macular degeneration (nAMD) treated with anti-vascular endothelial growth factor (anti-VEGF), according to the baseline best-corrected visual acuity (BCVA) based on the multicenter real-life data.
Methods: Five-hundred-ninety patients who had taken the Pro Re Nata (PRN) treatment regimen with three loading doses and at least one year of follow-up were included. The patients were divided into three groups according to the baseline BCVA: Group 1 (BCVA ≥ 1.3 Logmar), Group 2 (1.3 Logmar > BCVA ≥ 0.3 Logmar), and Group 3 (BCVA ≤ 0.2 Logmar). BCVA, central macular thickness (CMT), and the number of injections and visits were evaluated.
Results: There were 175, 322, and 93 patients in Group 1, Group 2, and Group 3, respectively. The number of visits and injections in the 1st year was not different between the groups (p = 0.58 and p = 0.08) and was 7.09 and 4.41 (Group 1), 6.59 and 5.58 (Group 2), 6.77 and 4.08 (Group 3). There was a significant difference in CMT between the baseline and 12th month in Group 1 and Group 2 (p < 0.001, p < 0.001, respectively) but not in Group 3 (p = 0.84). BCVA was significantly better in the 12th month in Group 1 (p < 0.001), slightly worse in Group 2 (p = 0.79), and significantly worse in Group 3 (p < 0.001).
Conclusion: This study provides evidence that an inadequate number of injections cannot protect vision. Moreover, it can cause vision loss, especially in the eyes with good vision.
Competing Interests: Declaration of Competing Interest The authors declare that they have no conflict of interest.
(Copyright © 2023 Elsevier B.V. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: